Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.
